SPDR S&P Biotech ETF
406 hedge funds and large institutions have $5.44B invested in SPDR S&P Biotech ETF in 2019 Q3 according to their latest regulatory filings, with 50 funds opening new positions, 118 increasing their positions, 136 reducing their positions, and 65 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
406
Holders Change
-18
Holders Change %
-4.25%
% of All Funds
8.92%
Holding in Top 10
10
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-33.33%
% of All Funds
0.22%
New
50
Increased
118
Reduced
136
Closed
65
Calls
$829M
Puts
$1.81B
Net Calls
-$982M
Net Calls Change
+$20.7M
Top Buyers
| 1 |
JPMorgan Chase & Co
New York
|
+$202M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$193M |
| 3 |
Citigroup
New York
|
+$149M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$83.8M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$59.9M |
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$250M |
| 2 |
Morgan Stanley
New York
|
-$112M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$67.7M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$50.3M |
| 5 |
Two Sigma Advisers
New York
|
-$39.8M |
